Eisai Co. Ltd.
Company Snapshot
Founded: 1941
Entity Type: Public
Employees: 10,917
Region: Japan
Revenue: $5,186.4 Millions
Revenue Year: 2024
Segment: Pharmaceutical business
Headquarter: Tokyo, Japan
Key Geographics: Japan, Americas, China, Europe, Middle East and Africa, Asia, Latin America
Corporate Address: 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan Tel. +81-3-3817-3700 www.eisai.com
Company Overview
Established in 1941, Eisai Co. Ltd. is a pharmaceutical company with a strong focus on prescription medicines. The company’s pharmaceuticals business comprises neurology, oncology, consumer healthcare, and other businesses. Eisai’s main global products include Leqembi, Lenvima, Dayvigo, Fycompa, and Halaven. Dementia is one of the key focus areas, and through its Deep Human Biology Learning (DHBL) approach to drug discovery and development, Eisai is concentrating on the R&D of therapeutic drugs for dementia. The company's goal is to develop innovative drugs with novel targets and mechanisms of action to help treat dementia, including AD.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Eisai Co. Ltd. In News
Company's Business Segments
- Pharmaceutical Business : This segment includes Lenvima, Dayvigo, Leqembi, Halaven, Fycompa.
- Other Business : Other business mainly includes the License Revenue, Pharmaceutical Ingredient Business of the company.
Applications/End User Industries
- Clinical Research
- Clinical Trials
- Oncology
- Drug Creation Research
- Drug Development
- Clinical Study Reports
- Statistical Analysis Plan
- Dementia
- Tropical Diseases
BCC Research Beacon 